Pequot Capital Sells the Bulk of Its Akorn Stake
Market Folly
•
Tue, Jun 23, 2009
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
623 people get AKRX articles and Market Currents by email alert.
Get email alerts on AKRX »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
5 Big Buys By Oak Ridge InvestmentsEfsinvestment • Sat, Nov 10, 2012 -
-
-
-
4 Healthcare Stocks Primed For GrowthZetaKap • Fri, Jul 27, 2012
-
-
-
-
-
-
-
-
4 Undervalued Healthcare Stocks Positively Correlated To VolatilityKapitall • Wed, Jun 13, 2012
-
-
-
4 High Earning Small Caps Poised For GrowthZetaKap • Tue, Jun 5, 2012
-
-
Akorn's CEO Discusses Q3 2012 Results - Earnings Call TranscriptTue, Nov 6, 2012
-
Akorn CEO Discusses Q2 2012 Results - Earnings Call TranscriptTue, Aug 7, 2012 • 1 Comment
-
Akorn, Inc. Q3 2008 Earnings Call TranscriptTue, Nov 18, 2008
-
Akorn, Inc. Q2 2008 Earnings Call TranscriptMon, Aug 25, 2008
-
Akorn, Inc. Q1 2008 Earnings Call TranscriptTue, May 13, 2008
-
Akorn, Inc. Q4 2007 Earnings Call TranscriptMon, Apr 14, 2008
-
Akorn Q3 2007 Earnings Call TranscriptFri, Nov 2, 2007 • 1 Comment
-
Business Wire (May 7, 2013)
-
PR Newswire (Apr 3, 2013)
-
Business Wire (Feb 26, 2013)
-
PR Newswire (Feb 5, 2013)
-
Business Wire (Jan 17, 2013)
-
PR Newswire (Jan 14, 2013)
-
Business Wire (Nov 6, 2012)
-
Business Wire (Oct 24, 2012)
-
PR Newswire (Oct 10, 2012)
-
Business Wire (Sep 24, 2012)
-
Business Wire (Aug 7, 2012)
-
Business Wire (Aug 7, 2012)
-
Business Wire (Aug 7, 2012)
-
at MarketWatch.com (Jul 23, 2012)
-
PR Newswire (Jul 6, 2012)
-
at MarketWatch.com (May 15, 2012)
-
Business Wire (May 8, 2012)
-
PR Newswire (Apr 17, 2012)
-
Business Wire (Apr 10, 2012)
-
at MarketWatch.com (Mar 7, 2012)
AKRX vs. ETF Alternatives
Company Description
Currently, there's no company description for AKRX.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 11:11 AM Akorn (AKRX -12.2%) takes a hit this morning after Q1 revenue results missed the mark. The company noted that due to constraints in capacity with its manufacturing partners as well as other market challenges, it was lagging behind with the launches of certain products that were approved late last year. It expects the issue to be resolved sometime in H2. Due to the problems however, it's lowering its forecast for FY13, now anticipating sales of $60M to $62M, or $0.53 to $0.55 per share - below Street expectations of $0.61. Comment! [Healthcare, On the Move, Earnings]
-
Tuesday, May 7, 9:13 AM
Premarket gainers: SNTS +11%. ALU +11%. CVLT +8%. HIMX +7%. NSM +7%. FOSL +6%. DTV +6%.
Losers: RKUS -24%. ARUN -17%. AKRX -7%. PAL -6%. 1 Comment [On the Move] - Tuesday, May 7, 6:09 AM Akorn (AKRX): Q1 EPS of $0.13 in-line. Revenue of $73.9M (+43% Y/Y) misses by $0.17M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
- Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
- Tuesday, February 26, 7:07 AM Akorn (AKRX): Q4 EPS of $0.13 beats by $0.01. Revenue of $71.5M (+68% Y/Y) beats by $2.08M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, February 26, 12:05 AM Notable earnings before Tuesday’s open: AG, AKRX, AMED, AMT, AUXL, AZO, BMO, BYD, CBRL, CIE, CMLP, CRZO, ECL, EXPD, GTI, HD, HFC, M,MFA, PCS, RRD, RSH, SKS, SPRD, SRE, THC, TSL, UNFI, UTHR Comment! [Earnings]
- Monday, February 25, 5:30 PM Notable earnings before Tuesday’s open: AG, AKRX, AMED, AMT, AUXL, AZO, BMO, BYD, CBRL, CIE, CMLP, CRZO, ECL, EXPD, GTI, HD, HFC, M,MFA, PCS, RRD, RSH, SKS, SPRD, SRE, THC, TSL, UNFI, UTHR Comment! [Earnings]
- Friday, January 18, 12:46 PM Shares of Akorn (AKRX -1.8%) slip after projecting its 2013 EPS to come in below Street estimates, despite forecasting record revenue as the niche pharmaceutical company boosts its product pipeline. It now expects to earn $0.57 to $0.61 per share, versus expectations of $0.66. Revenue is anticipated at $325M to $335M, in line with analysts projections of $331M. Read the transcript of the guidance conference here: (Transcript) Comment! [Healthcare, On the Move]
- Tuesday, November 6, 2012, 6:06 AM Akorn (AKRX): Q3 EPS of $0.14 beats by $0.01. Revenue of $69.6M (+90% Y/Y) beats by $1M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, November 6, 2012, 12:05 AM Notable earnings before Tuesday’s open: AKRX, AMED, AMSC, AOL, CPN, CRIS, CRZO, CSC, CVC, CVS, DISCA, DISH, DNR, DTV, DWRE, EMR, EXPD, FOSL, FTR, FUN, GEL, HCN, HL, HPT, ISIS, KWK, MFA, NYX, ODP, OMX, OXF, POM, SCG, SRE, VVUS 1 Comment [Earnings]
- Monday, November 5, 2012, 5:30 PM Notable earnings before Tuesday’s open: AKRX, AMED, AMSC, AOL, CPN, CRIS, CRZO, CSC, CVC, CVS, DISCA, DISH, DNR, DTV, DWRE, EMR, EXPD, FOSL, FTR, FUN, GEL, HCN, HL, HPT, ISIS, KWK, MFA, NYX, ODP, OMX, OXF, POM, SCG, SRE, VVUS Comment! [Earnings]
- Thursday, August 23, 2012, 2:19 PM Akorn (AKRX -0.4%) has reportedly received FDA approval for its generic version of of Allergan's (AGN) Alocril, a prescription eye drop for itchy allergy eyes. Comment! [Healthcare]
- Tuesday, August 7, 2012, 11:57 AM Shares of Akorn (AKRX +6.7%) move higher after its preliminary Q2 revenue beat estimates this morning. Revenue grew by 97% over the comparable prior year quarter or 37% excluding the impact of acquisitions. The company also guides its FY12 earnings higher, now expecting to earn between $0.50 - $0.52 on revenue of $248M - $258M, versus previous expectations of $0.44 - $0.46 per share on revenue of $228M - 238M. Comment! [Healthcare, On the Move]
- Tuesday, August 7, 2012, 7:44 AM Akorn (AKRX): Q2 EPS of $0.12 in-line. Revenue of $63.3M (+96.9% Y/Y) beats by $2M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, August 7, 2012, 12:05 AM Notable earnings before Tuesday’s open: AKRX, AMRC, APU, ARCC, ARCO, BPI, CHD, CRZO, CVC, CVS, DWRE, EBIX, EMR, ENDP, EXPD, FE, FOSL, GTE, HL, HPT, KITD, KWK, MEA, MGM, MMC, MNKD, MPEL, NIHD, ODP, PCG, POM, SIRI, SOL, STWD, TAP, THC, TIE Comment! [Earnings]